Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform
November 9, 2015 6:05 AM EST
Agios Pharma (NASDAQ: AGIO) announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
"Glioma, cholangiocarcinoma and chondrosarcomas are all extremely difficult-to-treat diseases with limited therapeutic options," said Howard Burris, M.D., Sarah Cannon Research Institute, an investigator for the study. "Today's Phase 1... More
November 5, 2015 8:01 AM EST
Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.08), $0.20 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $17.21 million.
Cash, cash equivalents and marketable securities as of September 30, 2015 were $408.0 million, compared to $467.4 million as... More
